Founded in Switzerland in June 2017, iOnctura is a late pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer.


iOnctura is developing a pipeline of carefully selected assets that target and modulate mechanisms that drive immuno-suppression in the tumour microenvironment (TME). We expect that rational combination of our pipeline with approved checkpoint inhibitors will maximize and boost the impact of first generation checkpoint inhibition.


Checkpoint inhibitors (e.g. anti PD1/PD-L1) have shown remarkable effectiveness for some but not all patients. The antitumor immune response of checkpoint inhibitors can be dampened by a hostile TME, consisting of a mixture of tumour associated cell types. Our strategy is to render the TME immune-permissive by targeting immuno-suppressive mechanisms with selective inhibitors, and to develop specific combinations with checkpoint inhibitors leading to breakthrough cancer treatments.

We have sourced a pipeline of assets that target the tumor microenvironment  through our collaborations with Merck KGaA, Darmstadt and the world’s leading cancer research organization, Cancer Research UK. Additionally we have gained privileged access to the supply of one of the leading PDx checkpoint inhibitors, avelumab*, for clinical trials.

*Avelumab is jointly developed by Merck KGaA, Darmstadt, Germany and Pfizer.